CEL-SCI Corp. | Income Statement

Fiscal year is October-September. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
159.60
264.00
657.40
285.10
69.00
476.60
SG&A Expense
19,641.10
25,857.00
33,047.50
24,479.90
20,774.40
16,598.70
EBIT
19,845.70
25,824.80
-
24,858.80
21,338.30
16,772.30
Unusual Expense
10,728.00
1,500.60
337.80
15,113.70
11,007.20
8,643.60
Interest Expense
170.40
163.80
1,964.20
1,879.40
4,032.20
6,492.30
Pretax Income
9,170.90
27,366.30
34,692.20
11,512.50
14,363.30
31,837.20
Consolidated Net Income
9,230.50
28,483.70
34,692.20
11,512.50
14,363.30
31,837.20
Net Income
9,230.50
28,483.70
34,692.20
11,512.50
14,363.30
31,837.20
Net Income After Extraordinaries
9,230.50
28,483.70
34,692.20
11,512.50
14,299.50
31,822.80
Net Income Available to Common
9,230.50
28,483.70
34,692.20
11,512.50
14,363.30
31,837.20
EPS (Basic)
16.50
12.25
10.51
2.37
1.83
1.87
Basic Shares Outstanding
1,211.20
2,352.20
3,300.80
4,866.20
7,891.80
17,004.70
EPS (Diluted)
16.50
12.22
10.51
2.37
1.83
1.87
Diluted Shares Outstanding
1,211.20
2,352.20
3,300.80
4,866.20
7,891.80
17,004.70
EBITDA
19,481.50
25,593.00
32,390.20
24,194.80
20,705.40
16,122.10
Non-Operating Interest Income
117.10
122.90
-
-
-
-
Other After Tax Income (Expense)
59.50
1,117.40
-
-
-
-

About CEL-SCI

View Profile
Address
8229 Boone Boulevard
Vienna Virginia 22182
United States
Employees -
Website http://www.cel-sci.com
Updated 07/08/2019
CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus or human papillomavirus co-infected patients.